MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

MDT

81.83

-0.81%↓

VEEV

209.89

-2.67%↓

A

100.29

-2.02%↓

WBA

10.86

-0.18%↓

CHE

562.75

-2.9%↓

Search

Merus NV

Cerrado

SectorSalud

43.02 0.3

Resumen

Variación precio

24h

Actual

Mínimo

42.66

Máximo

45.35

Métricas clave

By Trading Economics

Ingresos

-31M

Ventas

9.1M

BPA

-0.49

Margen de beneficio

-338.326

Empleados

260

EBITDA

-88M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+107.66% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

298M

2.9B

Apertura anterior

42.72

Cierre anterior

43.02

Noticias sobre sentimiento de mercado

By Acuity

25%

75%

64 / 385 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

Merus NV Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

21 abr 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

Nomura to Buy Macquarie's U.S., European Public Asset Management Business

21 abr 2025, 22:37 UTC

Adquisiciones, fusiones, absorciones

Hino Motors, Mitsubishi Fuso Moving Toward Merger, Nikkei Says

21 abr 2025, 23:58 UTC

Charlas de Mercado

Transurban on Bumpy Road During NSW Toll Review -- Market Talk

21 abr 2025, 23:46 UTC

Charlas de Mercado

Gold Rises Amid Likely Safe-Haven Demand -- Market Talk

21 abr 2025, 23:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

21 abr 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Decline as Uncertainty Over U.S. Trade Policy Continues -- Market Talk

21 abr 2025, 23:22 UTC

Adquisiciones, fusiones, absorciones

Nomura to Pay $1.8B for Macquarie's U.S. and European Public Asset-Management Business

21 abr 2025, 23:22 UTC

Adquisiciones, fusiones, absorciones

Nomura to Acquire Macquarie's U.S. and European Public Asset-Management Business

21 abr 2025, 22:35 UTC

Principales Noticias

Harvard Is Suing the Trump Administration -- 2nd Update

21 abr 2025, 22:02 UTC

Principales Noticias

Harvard Is Suing the Trump Administration -- Update

21 abr 2025, 21:46 UTC

Principales Noticias

Fed, Tariff Fears Send Dow Down More than 900 Points -- Update

21 abr 2025, 21:03 UTC

Principales Noticias

3M Earnings Will Be Scoured for Tariff Impacts -- Barrons.com

21 abr 2025, 21:03 UTC

Principales Noticias

Harvard Is Suing the Trump Administration -- WSJ

21 abr 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

21 abr 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

21 abr 2025, 20:43 UTC

Principales Noticias

GE Aerospace Investors Are Hoping for Reassurance, and Strong Earnings -- Barrons.com

21 abr 2025, 20:28 UTC

Principales Noticias

Fed, Tariff Fears Send Dow Down More than 900 Points -- WSJ

21 abr 2025, 20:26 UTC

Principales Noticias

Lockheed Martin's Earnings Are Coming as Investors Watch the Pentagon -- Barrons.com

21 abr 2025, 20:24 UTC

Principales Noticias

Dow and Dollar Drop on Jitters Over Fed and TradeHeadline -- WSJ

21 abr 2025, 20:18 UTC

Principales Noticias

Boeing 737 MAX Jets in China Head Home. Can They Be Resold? -- Barrons.com

21 abr 2025, 19:14 UTC

Charlas de Mercado

Oil Futures Give Back Pre-Holiday Gains -- Market Talk

21 abr 2025, 19:11 UTC

Charlas de Mercado

U.S. Natural Gas Falls as China Turns Elsewhere for LNG -- Market Talk

21 abr 2025, 19:07 UTC

Principales Noticias

Uber Faces FTC Lawsuit Alleging Deceptive Billing, Cancellation Practices -- Update

21 abr 2025, 18:44 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 abr 2025, 18:44 UTC

Charlas de Mercado

Trump Seen as Unlikely to Fire Powell Despite Market Jitters -- Market Talk

21 abr 2025, 18:28 UTC

Charlas de Mercado

Gold Finishes at New Record as Equities Slide -- Market Talk

21 abr 2025, 18:26 UTC

Principales Noticias

Dow Industrials, Dollar Fall on Fed and Trade Concerns -- WSJ

21 abr 2025, 16:27 UTC

Charlas de Mercado

Weaker Dollar No Longer Supporting Commodities Due to Fed Fears -- Market Talk

21 abr 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

21 abr 2025, 16:16 UTC

Principales Noticias

Dow and Dollar Drop on Jitters Over Fed and Trade -- WSJ

Comparación entre iguales

Cambio de precio

Merus NV Esperado

Precio Objetivo

By TipRanks

107.66% repunte

Estimación a 12 meses

Media 89.42 USD  107.66%

Máximo 110 USD

Mínimo 67 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Merus NV Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

15

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

43.215 / 43.46Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

64 / 385 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.